Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 16/20 | 0.72 |
| ▸ | CTSK | P43235 | 15/20 | 0.72 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13229651 | 0.89 | CTSK (0.59) | CTSSCTSKCAPN1CTSLCTSB | |
| SCHEMBL14611701 | 0.88 | CTSS (0.57) | CTSSCTSKCAPN1CTSLCTSB | |
| SCHEMBL2998867 | 0.87 | CTSS (0.56) | CTSSCTSKCAPN1CTSLCTSB | |
| SCHEMBL18975436 | 0.85 | CAPN1 (0.59) | CTSSCTSKCAPN1CTSLCTSB | |
| SCHEMBL3034859 | 0.85 | CTSS (0.58) | CTSSCTSKCAPN1CTSLCTSB | |
| SCHEMBL24741085 | 0.85 | CAPN1 (0.74) | CTSSCTSKCAPN1CTSLCTSB | |
| SCHEMBL21111329 | 0.85 | CTSS (0.67) | CTSSCTSKCAPN1CTSLCTSB | |
| SCHEMBL12336548 | 0.85 | CTSS (0.67) | CTSSCTSKCAPN1CTSLCTSB | |
| SCHEMBL3275039 | 0.85 | CTSS (0.67) | CTSSCTSKCAPN1CTSLCTSB | |
| SCHEMBL10076131 | 0.85 | CTSS (0.67) | CTSSCTSKCAPN1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204160-A1 | SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204160-A1 | SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| US-7713961-B2 | Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7713961-B2 | Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090325940-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090325940-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20080293680-A1 | Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II | PETERS STEFAN | 2008-11-27 | — | — | US | disclosed |
| US-20080293680-A1 | Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II | PETERS STEFAN | 2008-11-27 | — | — | US | disclosed |
| WO-2007014946-A1 | SUBSTITUTED ETHANE-1,2-DIAMINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204160-A1 | SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF | PSEN1, PSEN2, BACE1 | CTSS 1930/4885CTSK 3047/4885CAPN1 3358/4885 |
| US-20090325940-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | PSEN1, PSEN2, BACE1 | CTSS 1930/4885CTSK 3047/4885CAPN1 3358/4885 |
| US-20080293680-A1 | Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II | PSEN2, PSEN1, APP | CTSS 3897/4885CTSK 4324/4885CAPN1 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.